Sector News

BMS to invest in new cell therapy manufacturing site in Europe

April 25, 2021
Life sciences

Bristol Myers Squibb (BMS) is planning to invest in a new cell therapy manufacturing site based in Leiden in the Netherlands.

In a statement, BMS said that the new site would tap into the growing life sciences region near Amsterdam, as well as the ‘convenient access’ to transportation for shipping patient cells.

The new investment will expand BMS’ global manufacturing capacity for its cell therapy franchise, which includes the recently approved CAR T therapies Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel).

The Leiden site will become BMS’ fifth cell therapy manufacturing facility, and the company’s first in Europe.

It will be commercially focused, BMS added, with additional capabilities for multi-product cell therapy manufacturing and the ability to scale up capacity.

BMS said that the site will leverage ‘innovative’ technologies, while also utilising the latest manufacturing equipment and advanced digital systems.

“A key element of BMS’ commitment to cell therapy is our continuous investment in advanced manufacturing capabilities, from the expansion of our global network and capacity to treat patients to reduced turn around time and optimised costs,” said Ann Lee, senior vice president, cell therapy development & operations, BMS.

“We continue to grow our presence in Europe and the Netherlands, which offers an innovative life sciences hub and world class industry talent, and we look forward to hiring several hundred talented people over the coming years to join our global team and participate in our cell therapy journey,” she added.

The site design and development planning for the site is currently underway, with BMS anticipating construction to begin later this year.

by Lucy Parsons

Source: pharmatimes.com

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend